For orders processing please visit the order policy
BioClinic NMN 60 V-Cap
Artikelnummer 9428
BioClinic NMN Metabolically Active Nicotinamide Mononucleotide & NAD Precursor 150 Mg 60 V-Cap
NMN is a bioavailable precursor to nicotinamide adenine dinucleotide (NAD+), a key coenzyme needed for over 500 enzymatic reactions. As many of these enzymatic reactions are related to cellular metabolism, aging, inflammation, circadian rhythm, mitochondrial respiration, glycolysis, and DNA repair, NAD+ is considered critical to human health and longevity. NAD+ is also needed for the expression of sirtuins, enzymes with numerous cellular regulatory effects particularly important for inflammation, DNA repair, and energy metabolism. Considerable research shows a decline in NAD+ and sirtuin expression with aging, leading to an impairment of mitochondrial function and biogenesis and increased oxidative damage, driving the aging process itself as well as many diseases associated with aging, including cardiovascular and metabolic diseases.
Benefits
- Provides 150 mg of nicotinamide mononucleotide (NMN) per serving, shown to increase blood levels of NAD+ in clinical trials
- NMN is the immediate precursor to NAD+ and replenishes age-related decline in NAD+ levels
- NAD+ is a critical coenzyme for numerous pathways related to energy production, mitochondrial health, and DNA repair, and its decline is strongly associated with aging
- Vegetarian capsules with a clinically established dosage
NMN has been shown to significantly increase blood levels of NAD+ in human clinical trials, in part because it is only one enzymatic step from NAD+. Controlled clinical trials have demonstrated multiple benefits of NMN supplementation, including improvements in insulin sensitivity and signalling among women with impaired glucose metabolism, as well as aerobic capacity in healthy runners, and reduced drowsiness and improved sit-to-stand in older adults. Indicative of its potential to address aging pathways by restoring NAD+ levels, NMN supplementation for 12 weeks found a trend toward reduced arterial stiffness, an aging-related independent risk factor for cardiovascular and metabolic diseases.